The Safer Shrimp Imports Act directs the Secretary to extend FDA-like inspection oversight to foreign facilities that manufacture, process, pack, or hold shrimp bound for U.S. markets. It creates a process for foreign governments to enter arrangements with the United States to certify these facilities as meeting U.S. food safety standards.
The bill also ties import eligibility to those arrangements and to compliance with FDA-equivalent inspection criteria, with a parallel adulteration provision and annual reporting obligations. The aim is to reduce unsafe shrimp entering the United States and improve visibility over international supply chains.
For compliance professionals, importers, and industry observers, the bill signals a shift toward stricter, bilateral regulatory alignment on seafood safety. If enacted, shrimp from countries that do not establish arrangements or that fail FDA-equivalent criteria could face import barriers, while domestic and foreign stakeholders would need to align policies, testing, and enforcement practices with U.S. expectations.
At a Glance
What It Does
Establishes new requirements under FD&C Act section 807(c) to secure government-to-government arrangements for foreign shrimp facilities and to refuse shrimp imports from countries lacking such arrangements or equivalent inspection systems, effective one year after enactment. Adds an adulteration rule tying non-compliant foreign facilities to potential FDA enforcement under section 402(j).
Who It Affects
Foreign governments with shrimp facilities registered under section 415, U.S. health officials (FDA/HHS) and customs authorities, U.S. importers and distributors, and overseas facilities that ship shrimp to the United States.
Why It Matters
Creates an FDA-equivalence standard for overseas shrimp inspections, expanding U.S. oversight across the supply chain and potentially reshaping international trade relationships while aiming to reduce unsafe products in the market.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill introduces a new regime for overseas shrimp facilities that supply the United States. Within 180 days of enactment, the Secretary would seek to enter into arrangements with each foreign government that has shrimp facilities registered in the U.S. system to subject those facilities to inspections that are equivalent to FDA standards.
The core idea is to ensure foreign facilities adhere to U.S.-like safety controls before their shrimp can enter U.S. markets.
A key gatekeeping feature is timing. Beginning one year after enactment, shrimp from a country will be refused entry if that country does not have an arrangement with the Secretary, or if its food inspection system does not meet the FDA-equivalent criteria described in the bill.
The equivalence criteria focus on staffing and enforcement capacity to monitor shrimp production and transport to processing facilities, and the foreign government must demonstrate its system by providing all relevant laws, regulations, and related information to the Secretary.Additionally, the bill expands the adulteration framework. If shrimp imported into the United States has been manufactured, processed, packed, or held in a foreign country whose government or inspection system does not meet the required standards, that shrimp would be considered adulterated under the existing FD&C Act.
Finally, the Secretary must report to Congress on the implementation of these amendments not later than one year after enactment and annually thereafter, documenting progress, challenges, and any needed adjustments.Together, these provisions create a more stringent, two-layered gate—pre-approval through recognized foreign inspection equivalence and post-entry enforcement against non-compliant shipments—to reduce unsafe shrimp from entering the U.S. market. They also raise questions about supply chain resilience, compliance costs for foreign and domestic actors, and the practicality of achieving broad international agreement on standardized safety practices.
The Five Things You Need to Know
The bill adds 807(c) to require foreign shrimp facilities to be covered by FDA-like inspections via government-to-government arrangements within 180 days of enactment.
, 1 year after enactment, shrimp from countries without arrangements or with non-equivalent inspection systems may be refused entry to the United States.
, Equivalence criteria require foreign systems to match FDA shrimp inspection standards, including staffing for uniform enforcement and controls on how shrimp is raised and transported to processing facilities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Foreign shrimp facility inspection requirements
Adds 807(c) to the FD&C Act, mandating that the Secretary seek arrangements with foreign governments that host shrimp facilities registered under section 415. The goal is to ensure those facilities are subject to FDA‑style inspections before their shrimp may be sold in the United States. The mechanism centers on bilateral or multilateral arrangements that align foreign oversight with U.S. safety expectations.
Adulteration provisions for noncompliant imports
Amends FD&C Act section 402 by adding a new subsection (j): shrimp manufactured, processed, packed, or held in a foreign country whose inspection system does not comply with 807(c) would be adulterated under §402. This creates a direct enforcement link between foreign inspection adequacy and U.S. product eligibility.
Reporting on implementation
Requires the Secretary to report to Congress on the implementation of these amendments not later than one year after enactment and annually thereafter. The report covers progress, challenges, and any adjustments needed to operationalize the new arrangements and equivalence criteria.
This bill is one of many.
Codify tracks hundreds of bills on Trade across all five countries.
Explore Trade in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. consumers, who gain safer seafood through the reduction of unsafe shrimp entering the market.
- U.S. seafood importers and distributors with compliant supply chains, who gain clearer rules and reduced risk of accidental violations.
- Domestic shrimp processors and retailers who benefit from a more predictable safety regime and market stability.
- FDA and CBP, which gain stronger enforcement authority and clearer benchmarks for import screening.
- Foreign governments with shrimp inspection systems that meet FDA criteria, which gain quicker access to the U.S. market and recognition of their standards.
Who Bears the Cost
- Foreign governments and shrimp facilities that fail to establish arrangements or meet the FDA‑equivalent criteria face export restrictions and market access barriers.
- U.S. importers and distributors may incur higher compliance costs, supplier diversification needs, and potential short-term supply disruption.
- FDA/HS and CBP will need expanded resources and systems to implement additional inspections, data sharing, and enforcement.
- Domestic producers and consumers could face higher prices or tightened supply if noncompliant imports are reduced.
Key Issues
The Core Tension
The central dilemma is balancing stringent public health protections with the feasibility of global regulatory alignment. Strengthening safety checks via foreign equivalence could raise import barriers and costs, while insufficient alignment could leave U.S. consumers exposed to unsafe seafood.
The bill hardens the regulatory posture around imported shrimp by creating a formal gate based on foreign inspection credibility. The major policy tension is whether requiring foreign governments to adopt FDA‑like enforcement is feasible at scale and whether it could disrupt supply chains or raise costs for U.S. consumers.
Implementation hinges on foreign governments’ willingness to negotiate arrangements and on their ability to sustain staffing and enforcement comparable to the FDA. Even with arrangements, there is a potential for delays, disputes over what qualifies as “equivalent,” and questions about how quickly U.S. agencies can verify and monitor foreign controls.
Additionally, tying adulteration status to foreign inspection adequacy raises concerns about consistent enforcement, potential retaliation in trade, and the risk that a nominal alignment does not capture on-the-ground compliance. The annual reporting requirement is intended to provide visibility, but the bill does not specify mechanisms for issue-resolution if arrangements stall or if new public health data require rapid adjustments.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.